National University Ireland, Galway
The Regenerative Medicine Institute (REMEDI) is a Science Foundation Ireland-funded research centre focused on using stem cell and regenerative medicine technologies to treat human disease. Recognised as Ireland leading stem cell research centre, REMEDIs mission is to conduct basic research in stem cell biology and to translate and commercialize the results to regenerative therapeutics. Based at the National University of Ireland Galway, REMEDI is a collaboration between scientists, engineers, clinicians and industry.
REMEDI currently has focused research programmes in areas such as stem cell biology, immunology, gene therapy and cell manufacturing. To fulfil its translational mission, REMEDI manages and operates the Centre for Cell Manufacturing Ireland (CCMI), a facility licensed by the Irish Medicines Board to manufacture stem cells for human applications.
Researchers at REMEDI have to date coordinated three European Framework Programme 7-funded projects (Purstem, Reddstar and Visicort) and have partnered on four more (Gamba, Adipoa, Eurostemcell and Decide).
- Prof. Matthew Griffin is a REMEDI principal investigator and leads the REMEDI Immunology Group. He is a physician scientist with over 15 years of experience in basic immunology, clinical research and clinical practice applied to transplantation. Prior to joining the NUIG faculty in 2008, he trained and worked at The University of Chicago with Dr. Jeffrey Bluestone and at the Mayo Clinic Transplant Center in the US. He has been PI of major research grants from the NIH, Science Foundation Ireland, Mayo Clinic, Wyeth Pharmaceuticals, Abbott Laboratories and the Health Research Board of Ireland. He has published 88 original peer-review articles and 27 reviews and book chapters. His research experience spans pre-clinical investigation of immune diseases, systems biology-based profiling of human kidney transplant biopsy specimens, clinical research in transplantation and immunological investigation of stem cells. With Dr. Ritter, he will lead pre-clinical immune profiling studies and iSSC studies of CT as well as the development of interventional strategies for adverse immune responses to human CT. Prof. Griffin will also direct the VISICORT dissemination programme
- Dr. Thomas Ritter is a REMEDI principal investigator and member of the REMEDI Immunology Group. He is a leading researcher in the field of transplant immunology applied to corneal and other tissue transplants and stem cell therapies. He developed his expertise at Charité University in Berlin, Germany and the Centre d’Immunologie de Marseille-Luminy, France before joining the NUIG faculty in 2006. His laboratory has established rat models of corneal transplantation and a wide range of techniques for characterising local and systemic immune in these models. His research is funded by Science Foundation Ireland and the Health Research Board of Ireland.